SRX.AX - Sirtex Medical Limited

ASX - ASX Delayed Price. Currency in AUD

Sirtex Medical Limited

101 Miller Street
Level 33
Sydney, NSW 2060
61 2 9964 8400

Full Time Employees292

Key Executives

NameTitlePayExercisedYear Born
Mr. Andrew McLeanCEO & Exec. Director885.18kN/AN/A
Mr. Darren Smith M.B.A., B.Bus., FCPACFO & Company Sec.559.13kN/A1965
Mr. Nigel LangeChief Commercial Officer749.75kN/AN/A
Dr. Thomas Duthy Ph.D.Global Investor Relations Mang.N/AN/AN/A
Nathalie Amoury PharmdDirector of Global Marketing & CommunicationsN/AN/AN/A
Amounts are as of December 31, 2017 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in AUD.


Sirtex Medical Limited, a life-sciences company, develops and delivers oncology treatments using novel small particle technology in the Asia Pacific, Europe, the Middle East and Africa, and North and South America. Its lead product includes SIR-Spheres Y-90 resin microspheres, a targeted radiation therapy for the treatment of liver tumours. The company is headquartered in North Sydney, Australia.

Corporate Governance

Sirtex Medical Limited’s ISS Governance QualityScore as of April 1, 2018 is 10. The pillar scores are Audit: 1; Board: 10; Shareholder Rights: 1; Compensation: 10.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.